CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage biopharmaceutical company developing a novel class of tumor targeted therapies for initial application in primary tumors such as choroidal melanoma, today announced the dosing of the…
Category: News
Nouvelles données sur Enspryng (Satralizumab) de Chugai sur le risque et la sévérité des rechutes dans le trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé la présentation de nouvelles données sur Enspryng® (nom générique : satralizumab [recombinaison génétique]) dans la réduction de la sévérité des rechutes dans le traitemen…
Readers Predict Biggest Medical Breakthroughs by 2045
As part of Medscape’s 25th anniversary, readers were asked what they predict will change medicine in the next 25 years. Gene therapy advances and cancer cures topped the list. Medscape Medical News
Study may expedite the process to cure blindness and macular degeneration
While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of the eye and its diseases at the cellular level.
Samenvatting: Nieuwe gegevens van Chugai’s Enspryng (Satralizumab) over risico en ernst van terugval bij neuromyelitis optica spectrum disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kondigde de presentatie aan van nieuwe Enspryng® (generieke naam: satralizumab [genetische recombinatie]) gegevens over het verminderen van de ernst van terugval bij de behandeling v…
Resumen: Nuevos datos de Enspryng (satralizumab) de Chugai sobre el riesgo y la gravedad de la recaída en el trastorno del espectro óptico de la neuromielitis (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKIO:4519) ha anunciado la presentación de nuevos datos de Enspryng® (nombre genérico: satralizumab [recombinación genética]) sobre la reducción de la gravedad de las recaídas en el tratamiento …
National Eye Institute grant supports research initiatives in major vision- robbing conditions
A $3 million National Eye Institute grant is enabling the critical infrastructure necessary to grow research initiatives in major vision-robbing conditions at the Medical College of Georgia and Augusta University.
Nonharmful stress promotes disease resilience in offspring, shows study
Research led by Jeff Gidday, PhD, Professor of Ophthalmology, Biochemistry, Neuroscience, and Physiology at LSU Health New Orleans School of Medicine, reports what is believed to be the first study in a mammalian model documenting the reprogramming of …
Oxygen-Releasing Bioink to Enhance Cell Survival in 3D Printed Structures
Researchers at the Terasaki Institute for Biomedical Innovation in Los Angeles, California have developed an oxygen-releasing bioink that may be useful in 3D printing bioengineered cell constructs. This can help live cells to survive in limited oxygen environments, such as those that exist inside of 3D printed devices, in the first days after impla (Read more...)
Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chie…
Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a ke…
Ashvattha Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced that Jeffre…
Immunomic Therapeutics Inc. Expands into South Korea
SEOUL–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, originating in the United States recently opened its first office in Sout…
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Riassunto: In arrivo i nuovi dati riguardanti Enspryng (satralizumab) di Chugai sul rischio e la gravità delle recidive nel disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) ha annunciato la presentazione di nuovi dati su Enspryng® (nome generico: satralizumab [ricombinazione genetica]) riguardo alla riduzione della gravità delle recidive nel trattamento …
New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)– #NMOSD–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced the presentation of new Enspryng® (generic name: satralizumab [genetical recombination]) data on reducing relapse severity in the treatment of neuromyelitis optica …
Hyperpolarized Gas MRI for Pulmonary Disease Assessment: Interview with Richard Hullihen, CEO of Polarean Imaging
Polarean Imaging, a company based in North Carolina, is pursuing regulatory approval for clinical use of its hyperpolarized gas MRI. The technology is intended to assist in diagnosing respiratory conditions, something that would be particularly useful during the ongoing COVID-19 pandemic. Specifically, Polarean produces equipment to generate hyperp (Read more...)
Laser-Controlled Microrobots Small Enough for Injections
Microrobotics researchers have been working for decades, in a seemingly futile attempt, to keep up with the miniaturization that has been achieved in the field of microelectronics. Although rudimentary microscopic robots have been developed, they have failed to take full advantage of conventional silicon electronics and so are limited in their func (Read more...)
Electrocorticography Implant for Plug and Play Brain-Computer Control
Researchers at UC San Francisco have used an electrocorticography (ECoG) implant to develop a brain-computer interface that does not need to be recalibrated and retrained each time it is used, allowing an experienced user to plug in and begin using the system at any time. The technique could allow for brain controlled prosthetic limbs or […]
(Read more...)Lid Lag or ‘Sand in My Eyes’ — What Could They Mean?
The Curbsiders choose their favorite practice-changing tips on hyperthyroidism. The Curbsiders